Bringing health-related life science and technology sectors into IMI2

With the entry into force of IMI 2, IMI welcomes the participation of non-pharmaceutical partners in its consortia established under the IMI2 regulation. These include, among others, the organisations from the knowledge management, IT, diagnostics, imaging, medical devices and animal health sectors.

This event was the first in a series of workshops, and it targeted companies and their umbrella organisations that share the goals of IMI2 and are interested in joining IMI’s activities. The event was a dynamic, hands-on workshop to exchange views, information and innovative ideas for successful partnerships. The goals of this event were:

• To understand what technologies, expertise and approaches from non-pharmaceutical companies and sectors can support the objectives of the IMI2 Strategic Research Agenda; 
• To explain different pathways for other organisations to take part in IMI activities.

Draft agenda and programme outline

Dowload the agenda

Presentations

• Introduction to IMI2: an engine for therapeutic innovation
  Michel Goldman, IMI
• IMI2 Strategic Research Agenda
  Salah-Dine Chibout, Novartis
• Imaging for drug safety evaluation 
  Gunnar Schuetz, Bayer, IMI SGG Translational Safety
• Imaging activities within IMIDIA
  Jacob Hecksher-Sørensen, NovoNordisk, IMIDIA
• Linking clinical neuropsychiatry and quantitative neurobiology: NeuroPsy 
  Hugh Marston, Eli Lilly, NeuroPsy
• Data and knowledge management SGG - Enabling platorms and RADAR
  Anthony Rowe, Janssen, SGG Data and Knowledge management, RADAR
• Improving clinical and pre-clinical data analysis 
  Dominique Brees, Novartis Institutes for Biomedical Research, SGG Translational Safety
• Different routes to join and partner with IMI2 
  Irene Norstedt, European Commission
  Magda Chlebus, EFPIA